Knowledge HQ

All
Publications

Innovative Development of Closed CAR-T Platform

This poster describes a modular, closed CAR-T manufacturing platform. It details expansion strategies using G-Rex 100MCS for low doses and a two-step process with G-Rex 500MCS for high doses, consistently achieving high cell viability and yields.
Download Now
Publications

P09.13 OPTIMIZATION OF A GMP-GRADE LARGE-SCALE EXPANSION PROTOCOL FOR CYTOKINE-INDUCED KILLER CELLS USING GAS-PERMEABLE STATIC CULTURE

This study developed a GMP-compliant protocol for expanding CIK cells using G-Rex gas-permeable. G-Rex6 well plates yielded superior expansion and cytotoxicity compared to standard or G-Rex6M, achieving 400-fold expansion with minimal manipulation.
Download Now
Publications

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

This study demonstrates that anti-CD147 CAR-T and CAR-NK cells effectively kill hepatocellular carcinoma cells. To minimize toxicity, a logic-gated GPC3-synNotch system was developed. Transduced NK cells were maintained and expanded in G-Rex 6 multi-well cell culture plates with IL-2.
Download Now
Publications

Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis

This study uses targeted scRNA-seq and protein analysis to characterize human CD4+ T cells. It identifies CD80 and CD86 as markers of activated Tregs. Tregs were expanded in G-Rex, confirming that activation induces B7 molecule expression, revealing new insights into Treg biology and heterogeneity.
Download Now
Publications

Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients

This study reports the preclinical validation of ISIKOK-19 CD19 CAR-T cells for a Turkish clinical trial. Using G-Rex 100M for expansion and BX-795 to enhance transduction, researchers produced effective CAR-T cells that eliminated tumors in vivo, demonstrating a robust and cost-effective manufacturing process.
Download Now
Publications

Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model

This study evaluates the efficacy of intracerebroventricular (i.c.v.) delivery of piggyBac CD19 CAR T cells for CNS ALL. I.c.v. delivery eliminated CNS leukemia in mice, whereas intravenous delivery had only partial effects. The study supports direct CNS delivery as a potential therapeutic strategy.
Download Now
Publications

Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

This study evaluates allogeneic FLT3 CAR T cells with a safety off-switch for AML. Expanded in G-Rex plates, these cells showed potent antileukemic activity. The off-switch allowed depletion of CAR T cells to mitigate myelotoxicity and enable bone marrow recovery, supporting clinical development.
Download Now
Publications

Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity

This study presents a bifunctional fusion protein combining anti-PD-1 antibody with an engineered IL-21 mutein. Using G-Rex for cell culture, the fusion protein demonstrated targeted IL-21 delivery to PD-1+ T cells, enhancing cytotoxicity and tumor control in mice while minimizing off-target effects.
Download Now
Publications

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity

This research demonstrates that oncolytic adenovirus coding for TNFa and IL-2 remodels the ovarian tumor microenvironment. TILs expanded in G-Rex plates showed enhanced antitumor reactivity against autologous tumors treated with the virus. The strategy offers a promising combinatorial approach for ovarian cancer.
Download Now
Publications

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing

This study compares five CD123-CAR constructs to select a candidate for clinical trials in AML. Using G-Rex plates for expansion, researchers identified a CD28.CD28z CAR with superior expression and function. This construct was selected for a phase 1 clinical study targeting relapsed/refractory AML.
Download Now
Publications

RELY-30: Phase I Study of Relapsed CD30 Expressing Lymphoma Treated with CD30 CAR T Cells

This document outlines the protocol for the RELY-30 Phase I study evaluating CD30 CAR T cells in relapsed CD30+ lymphoma. It details patient eligibility, treatment plans, and safety monitoring. The protocol aims to assess the safety and efficacy of CAR T cells following lymphodepleting chemotherapy.
Download Now
Publications

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

This phase I/II study evaluates autologous CD30 CAR-T cells in relapsed/refractory Hodgkin lymphoma. Fludarabine-based lymphodepletion led to high response rates and durability. The therapy was safe with no neurotoxicity. The study highlights the potential of CD30 CAR-Ts for heavily pretreated patients.
Download Now

ScaleReady is a joint venture between Wilson Wolf Manufacturing and Bio-Techne.